Tromboprofilaxis durante el embarazo

Autor: Mario Santiago-Mesa, Juan David Vega, Nubia Mercedes González-Jiménez, Gina Sofía Montaño, Monica Paola Quemba
Rok vydání: 2020
Předmět:
Zdroj: Revista de la Facultad de Medicina. 68
ISSN: 2357-3848
0120-0011
DOI: 10.15446/revfacmed.v68n2.73366
Popis: espanolIntroduccion. En mujeres, el riesgo de desarrollar enfermedad tromboembolica venosa (ETV) es 5 a 6 veces mayor durante el embarazo, riesgo que puede aumentar considerablemente si existen antecedentes personales o familiares de otros estados protromboticos. La ETV es una de las principales causas de morbimortalidad en esta poblacion, por lo que para evaluar la pertinencia de usar tromboprofilaxis, ya sea farmacologica o no farmacologica, es necesario reconocer oportunamente los factores de riesgo clinico asociados a esta condicion. Objetivo. Describir el uso de pruebas de tamizaje de estados protromboticos y de la tromboprofilaxis farmacologica y no farmacologica para prevenir la ETV durante la gestacion, durante el parto y durante el puerperio. Materiales y metodos. Se realizo una revision de la literatura en Embase, ClinicalKey, ScienceDirect, Access Medicine, Scopus, ProQuest, PubMed y LILACS. Se buscaron estudios sobre trombofilia y tromboprofilaxis en el embarazo publicados entre enero de 2004 y marzo de 2018 en ingles y en espanol. Resultados. En la busqueda inicial se identificaron 126 articulos, de los cuales 52 cumplieron los criterios de inclusion. La mayoria de estudios correspondio a revisiones narrativas (n=15), revisiones sistematicas (n=8) y guias de practica clinica (n=6). Conclusion. Se recomienda el uso de pruebas de tamizaje de estados protromboticos durante la gestacion, el parto y el puerperio, ya que la identificacion oportuna de la ETV permite disminuir las tasas de morbimortalidad en esta poblacion mediante la implementacion de medidas tromboprofilacticas, sean o no farmacologicas. EnglishIntroduction: The risk of developing venous thromboembolism (VTE) in women is 5 to 6 times higher during pregnancy. In addition, this risk can be significantly higher if the patient has a history or family history of hypercoagulate states. VTE is a leading cause of morbidity and mortality in this population, so in order to assess if it is appropriate to use thromboprophylaxis during pregnancy, whether pharmacological or non-pharmacological, it is necessary to timely recognize the clinical risk factors associated with this condition. Objective: To describe the use, on the one hand, of screening tests for hypercoagulate states and, on the other, of pharmacological and non-pharmacological thromboprophylaxis to prevent the development of VTE during pregnancy, labor and the puerperium Materials and methods: A literature review was conducted in the Embase, ClinicalKey, ScienceDirect, Acces Medicine, Scopus, ProQuest, PubMed and LILACS databases. The search included studies on thrombophilia and thrombophylaxis during pregnancy published in English or Spanish between January 2004 and March 2018. Results: After completing the initial search, 126 studies were identified, of which 52 met the inclusion criteria. Most studies were narrative reviews (n=15), systematic reviews (n=8) and clinical practice guidelines (n=6). Conclusion: The use of screening tests for hypercoagulate states during pregnancy, labor and the puerperium is recommended, since the timely identification of VTE will allow the reduction of morbidity and mortality rates in this population through the implementation of thromboprophylactic measures, whether they are pharmacological or non-pharmacological.
Databáze: OpenAIRE
Externí odkaz: